Published in BMC Psychiatry on August 25, 2016
Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs (2005) 5.84
Oxidative stress and metabolic syndrome. Life Sci (2009) 2.41
Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet (2013) 1.96
The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophr Res (2006) 1.66
Effects of oxidative stress on fatty acid- and one-carbon-metabolism in psychiatric and cardiovascular disease comorbidity. Acta Psychiatr Scand (2014) 1.65
Bimodal distribution of polyunsaturated fatty acids in schizophrenia suggests two endophenotypes of the disorder. Biol Psychiatry (2011) 1.60
Abundant genetic overlap between blood lipids and immune-mediated diseases indicates shared molecular genetic mechanisms. PLoS One (2015) 1.48
Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev (2010) 1.38
Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration. Prog Lipid Res (2013) 1.37
Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry (2000) 1.30
Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry (2015) 1.29
High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res (2008) 1.24
Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res (2002) 1.16
Oxidative stress and metabolic pathologies: from an adipocentric point of view. Oxid Med Cell Longev (2014) 1.16
Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin Exp Pharmacol Physiol (2010) 1.11
The membrane hypothesis of schizophrenia. Schizophr Res (1994) 1.08
Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2013) 1.08
Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry (2009) 1.06
Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res (2012) 1.05
Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand (2004) 1.04
Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev (2010) 1.04
Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophr Res (2003) 1.03
Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr Res (2014) 1.02
Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients. Schizophr Res (2013) 1.01
Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci (2007) 0.99
Fatty acids and oxidative stress in psychiatric disorders. BMC Psychiatry (2008) 0.99
Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry Suppl (2004) 0.98
Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. Mol Psychiatry (2016) 0.96
Inflammatory markers in hyperlipidemia: from experimental models to clinical practice. Curr Pharm Des (2011) 0.94
A meta-analysis of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia. Schizophr Res (2012) 0.93
Impaired plasmalogens in patients with schizophrenia. Psychiatry Res (2012) 0.93
In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [(11)C]DPA-713 PET and analysis of CSF and plasma. Transl Psychiatry (2016) 0.92
Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System. Mol Neurobiol (2015) 0.92
Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.92
Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics. PLoS One (2013) 0.91
The symptom and function dimensions of the Global Assessment of Functioning (GAF) scale. Compr Psychiatry (2011) 0.91
C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Mol Psychiatry (2015) 0.90
The role of inflammation in schizophrenia. Front Neurosci (2015) 0.89
Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophr Res (2013) 0.89
Oxidative stress and psychological disorders. Curr Neuropharmacol (2014) 0.88
Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. Psychiatr Clin North Am (2003) 0.88
Association between serum lipids and membrane fatty acids and clinical characteristics in patients with schizophrenia. Acta Psychiatr Scand (2015) 0.87
Impaired metabolic reactivity to oxidative stress in early psychosis patients. Schizophr Bull (2014) 0.85
Potential biomarkers in psychiatry: focus on the cholesterol system. J Cell Mol Med (2012) 0.85
Clinical and biochemical validation of two endophenotypes of schizophrenia defined by levels of polyunsaturated fatty acids in red blood cells. Prostaglandins Leukot Essent Fatty Acids (2012) 0.85
A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia. Transl Psychiatry (2013) 0.83
Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naive patients at the onset of psychosis. Schizophr Res (1994) 0.83
Oxidized cholesterol as the driving force behind the development of Alzheimer's disease. Front Aging Neurosci (2015) 0.83
Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.82
Serum lipids in schizophrenia and other functional psychoses: a general population northern Finland 1966 birth cohort survey. Acta Psychiatr Scand (2004) 0.82
Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein. Schizophr Res (2012) 0.81
Lipid peroxidation in patients with schizophrenia. Psychiatry Clin Neurosci (2010) 0.81
Polyunsaturated fatty acid-phospholipid remodeling and inflammation. Curr Opin Endocrinol Diabetes Obes (2015) 0.80
Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol. Schizophr Res (2011) 0.80
The science of fatty acids and inflammation. Adv Nutr (2015) 0.79
Biomarkers for drug development in early psychosis: Current issues and promising directions. Eur Neuropsychopharmacol (2016) 0.78
Membrane fatty acid levels as a predictor of treatment response in chronic schizophrenia. Psychiatry Res (2011) 0.78
Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophrenia. Psychiatry Res (2009) 0.78
Membrane Damage Induced by Amyloid Beta and a Potential Link with Neuroinflammation. Curr Pharm Des (2016) 0.77
Altered phospholipid metabolism in schizophrenia: a phosphorus 31 nuclear magnetic resonance spectroscopy study. Psychiatry Res (2013) 0.76
Inflammatory evidence for the psychosis continuum model. Psychoneuroendocrinology (2016) 0.76
Associations of oxidative stress status parameters with traditional cardiovascular disease risk factors in patients with schizophrenia. Scand J Clin Lab Invest (2014) 0.76
Erythrocyte membrane polyunsaturated fatty acid (pufa) levels in a sample of patients with schizophrenia and relation with clinical and progression variables. Actas Esp Psiquiatr (2015) 0.76
Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nat Genet (2016) 1.02
Genome-wide analyses for personality traits identify six genomic loci and show correlations with psychiatric disorders. Nat Genet (2016) 0.82
Leveraging Genomic Annotations and Pleiotropic Enrichment for Improved Replication Rates in Schizophrenia GWAS. PLoS Genet (2016) 0.80
Genome-wide association study reveals greater polygenic loading for schizophrenia in cases with a family history of illness. Am J Med Genet B Neuropsychiatr Genet (2015) 0.76
Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer. BMC Genomics (2017) 0.75
4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients. Br J Clin Pharmacol (2017) 0.75